SOURCE: Solos Endoscopy, Inc.

January 23, 2007 08:23 ET

Solos Endoscopy Announced Its Worldwide Introduction of Its New System for the Early Detection of Breast Cancer

BOSTON, MA -- (MARKET WIRE) -- January 23, 2007 -- Solos Endoscopy, Inc. (PINKSHEETS: SLSY) announced today that the Company has launched worldwide its new Solos Breast Endoscopy System. Solos Endoscopy will roll out the system to hospitals and doctors throughout the world. The Solos Breast Endoscopy System is ideal for performing Mammary Ductoscopy procedures, which allows physicians to examine the mammary ducts under direct visualization. Clinical studies have shown that Breast Endoscopy (Mammary Ductoscopy) is capable of visualizing lesions consistent with ADH and early stages of cancer at dramatically smaller sizes than is currently possible through mammography. With the Solos System, physicians worldwide can find breast cancer and precancerous breast lesions as small as 0.2mm in diameter. This is 25 times smaller than is typically seen on a standard mammogram. This means the tumor can be found up to 5 years earlier -- while still confined within the mammary ducts where treatment survival rates of 99% have been reported. The Company will be posting information on the new system on their website at www.solosendoscopy.com.

The Solos Breast Endoscopy System employs advanced microendoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of breast cancers arise. The system is a versatile and customizable piece of medical equipment that can support multiple procedures including biopsies, lumpectomies, and other intraductal procedures. The Solos Breast Endoscopy System has the potential to help the early diagnosis of more than 1 million cases of breast cancer discovered each year throughout the world.

"We are pleased with the development of our Breast Endoscopy System and the many benefits it offers to women's healthcare providers and especially the women themselves. This product could significantly help to redefine the breast cancer detection market and we believe that our marketing campaign will help increase international awareness for this life saving technology," stated Bob Segersten, President of Solos Endoscopy, Inc.

Solos Endoscopy, Inc. recently announced the selection of Joseph N. Gassman as Vice President of International Sales. The position is pivotal in the Company's efforts to expand its presence in the European market. Mr. Gassman has 30 years of sales and management experience in the medical industry and has focused on medical devices, covering both capital equipment and disposable surgical products.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office.

Additional information is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact Information

  • Contact:
    Solos Endoscopy, Inc.
    Investor Relations
    1-866-THE-APPL(E)